New drug duo aims to shrink tumors before liver cancer surgery
NCT ID NCT07324824
Summary
This study is testing a combination of two drugs, sintilimab and bevacizumab, given to patients before they have surgery to remove liver cancer. The goal is to see if this 'pre-surgery' treatment can help lower the high chance of the cancer returning after the operation. The trial will enroll 37 adults with a specific type of operable liver cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.